Advertisement

International Journal of Colorectal Disease

, Volume 33, Issue 7, pp 967–971 | Cite as

Time between suspected and confirmed diagnoses of Crohn’s disease and ulcerative colitis in patients followed in gastroenterological practices in Germany

  • Karel Kostev
  • Marcel Konrad
  • Louis Jacob
Original Article

Abstract

Aims

The goal of the present study was to analyze the time between suspected and confirmed diagnoses of Crohn’s disease (CD) and ulcerative colitis (UC) in patients followed in gastroenterological practices in Germany.

Methods

The study included individuals who received a suspected diagnosis of CD or UC (index date) and were followed in 47 gastroenterological practices in Germany between January 2007 and December 2016. The main outcome measure of the study was the time between suspected and confirmed diagnoses of CD and UC. Covariables included age, sex, and type of health insurance (private or statutory). A multivariate linear regression model was used to analyze the impact of the different variables on the time between suspected and confirmed diagnoses of CD and UC.

Results

The study included 2657 patients with a suspected diagnosis of CD and UC between 2007 and 2016. The mean age was 39.7 (SD 15.9) and 41.3 (16.8) in the CD and UC groups, respectively. Median time between suspected and confirmed diagnoses was 46 days in the CD group and 43 days in the UC group. Median time ranged from 8 to 112 days in the different gastroenterology practices and was significantly shorter in individuals with private health insurance coverage than in those with statutory health insurance.

Conclusions

Median time between suspected and confirmed diagnoses of CD or UC was around 45 days in patients followed in gastroenterological practices in Germany. Health insurance was the only factor to have a significant impact on this time.

Keywords

Crohn’s disease Ulcerative colitis Time between suspected and confirmed diagnoses Risk factors Gastroenterological practices 

Notes

Funding

The authors have received no financial support for the research, authorship, and/or publication of this article.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, JCY W, FKL C et al (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390:2769–2778.  https://doi.org/10.1016/S0140-6736(17)32448-0 CrossRefPubMedGoogle Scholar
  2. 2.
    Hein R, Köster I, Bollschweiler E, Schubert I (2014) Prevalence of inflammatory bowel disease: estimates for 2010 and trends in Germany from a large insurance-based regional cohort. Scand J Gastroenterol 49:1325–1335.  https://doi.org/10.3109/00365521.2014.962605 PubMedCrossRefGoogle Scholar
  3. 3.
    Stark R, König H-H, Leidl R (2006) Costs of inflammatory bowel disease in Germany. PharmacoEconomics 24:797–814CrossRefPubMedGoogle Scholar
  4. 4.
    D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet Lond Engl 371:660–667.  https://doi.org/10.1016/S0140-6736(08)60304-9 CrossRefGoogle Scholar
  5. 5.
    Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ (2011) Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141:1194–1201.  https://doi.org/10.1053/j.gastro.2011.06.054 CrossRefPubMedGoogle Scholar
  6. 6.
    Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM, Swiss IBD Cohort Study Group (2012) Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 18:496–505.  https://doi.org/10.1002/ibd.21719 CrossRefPubMedGoogle Scholar
  7. 7.
    Degen A, Büning C, Siegmund B, Prager M, Maul J, Preiss JC, Wiedenmann BH, Sturm A, Schirbel A (2013) Mo1334 reasons for the delay of diagnosis in inflammatory bowel disease. Gastroenterology 144:S–639–S–640.  https://doi.org/10.1016/S0016-5085(13)62367-7 CrossRefGoogle Scholar
  8. 8.
    Fiorino G, Danese S (2016) Diagnostic delay in Crohn’s disease: time for red flags. Dig Dis Sci 61:3097–3098.  https://doi.org/10.1007/s10620-016-4298-8 CrossRefPubMedGoogle Scholar
  9. 9.
    Cantoro L, Di Sabatino A, Papi C, Margagnoni G, Ardizzone S, Giuffrida P, Giannarelli D, Massari A, Monterubbianesi R, Lenti MV et al (2017) The time course of diagnostic delay in inflammatory bowel disease over the last sixty years: an Italian multicentre study. J Crohns Colitis 11:975–980.  https://doi.org/10.1093/ecco-jcc/jjx041 CrossRefPubMedGoogle Scholar
  10. 10.
    Lee D, Koo JS, Choe JW, Suh SJ, Kim SY, Hyun JJ, Jung SW, Jung YK, Yim HJ, Lee SW (2017) Diagnostic delay in inflammatory bowel disease increases the risk of intestinal surgery. World J Gastroenterol 23:6474–6481.  https://doi.org/10.3748/wjg.v23.i35.6474 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ricciuto A, Fish JR, Tomalty DE, Carman N, Crowley E, Popalis C, Muise A, Walters TD, Griffiths AM, Church PC (2017) Diagnostic delay in Canadian children with inflammatory bowel disease is more common in Crohn’s disease and associated with decreased height. Arch Dis Child.  https://doi.org/10.1136/archdischild-2017-313060
  12. 12.
    Dombrowski S, Kostev K (2017) Use of electronic medical records in the epidemiological research [internet]. Cuvillier VerlagGoogle Scholar
  13. 13.
    Becher H, Kostev K, Schröder-Bernhardi D (2009) Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 47:617–626CrossRefPubMedGoogle Scholar
  14. 14.
    Schiffner R, Kostev K, Gothe H (2016) Do patients with lactose intolerance exhibit more frequent comorbidities than patients without lactose intolerance? An analysis of routine data from German medical practices. Ann Gastroenterol 29(2):174–179CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kostev K, Winiarski M, Schüller L, Sesterhenn AM, Jacob L (2018) Frequency of thyroid-stimulating hormone monitoring in patients after thyroidectomy: a retrospective study in primary care practices in Germany. Exp Clin Endocrinol Diabetes.  https://doi.org/10.1055/s-0044-100038
  16. 16.
    Muigai J, Jacob L, Dinas K, Kostev K, Kalder M (2018) Potential delay in the diagnosis of vulvar cancer and associated risk factors in women treated in German gynecological practices. Oncotarget 9:8725–8730.  https://doi.org/10.18632/oncotarget.23848 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.EpidemiologyIQVIAFrankfurt am MainGermany
  2. 2.Health & SocialesFOM UniversityFrankfurt am MainGermany
  3. 3.Faculty of MedicineUniversity of Paris 5ParisFrance

Personalised recommendations